Close
Biotechgate
| |

Home Page

Action required: Please refresh your browser

We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.

More details about this topic are available here »

ARTHEx Biotech Announces Participation at the 23rd Annual Needham Virtual Healthcare Conference
By: PR Newswire Association LLC. - 03 Apr 2024Back to overview list

VALENCIA, Spain, April 3, 2024 /PRNewswire/ -- ARTHEx Biotech S.L., a clinical-stage biotechnology company focused on developing innovative medicines through the modulation of microRNAs, today announced its participation in the 23rd Annual Needham Virtual Healthcare Conference, being held in a virtual format, April 8-11, 2024. Company management will meet with investors in one-on-one meetings during the conference.

About ARTHEx Biotech

ARTHEx Biotech is a clinical-stage biotechnology company focused on developing innovative medicines through the modulation of microRNAs. The Company's lead investigational compound, ATX-01, is being evaluated for the treatment of myotonic dystrophy type 1 (DM1), a rare neuromuscular disorder, in the Phase I-IIa ArthemiR™ trial. ARTHEx is also advancing its in-house discovery engine to identify and develop microRNA modulators for other disorders with high unmet medical needs, including genetically-driven diseases like DM1. The Company headquarters are in Valencia, Spain.

For more information, please visit www.arthexbiotech.com and engage with us on LinkedIn.

Company Contact. 

Investor and Media Contact

Frédéric Legros 

Amy Conrad

Executive Chairman and CEO

Juniper Point

flegros@arthexbiotech.com       

amy@juniper-point.com

+33679495790

+1 858-366-3243

 

ARTHEx logo (PRNewsfoto/ARTHEx Biotech)

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/arthex-biotech-announces-participation-at-the-23rd-annual-needham-virtual-healthcare-conference-302106329.html

SOURCE ARTHEx Biotech

Copyright 2024 PR Newswire Association LLC. Back to overview list
to the top ↑